Antibody therapy for acute lymphoblastic leukemia.

Advances in chemotherapy administration have made acute lymphoblastic leukemia (ALL) a curable disease; however, most patients will relapse, despite readily attaining a complete remission. Treatment of relapse has shown dismal results with little advances made in the recent decades. Antigenic-directed therapy of ALL can complement cytotoxic chemotherapy and has shown encouraging results. This review will evaluate four antigens in ALL (CD20, CD22, CD52, and CD19) and therapeutic strategies to target them. We will review the clinical and preclinical data surrounding rituximab, epratuzumab, inotuzumab ozogamicin, alemtuzumab, blinatumomab, and chimeric antigen receptor-modified T-cell therapy.
AuthorsCraig A Portell, Anjali S Advani
JournalCurrent hematologic malignancy reports (Curr Hematol Malig Rep) Vol. 7 Issue 2 Pg. 153-9 (Jun 2012) ISSN: 1558-822X [Electronic] United States
PMID22422550 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Antigens, CD
  • Antineoplastic Agents
  • Immunologic Factors
  • Antibodies, Monoclonal (therapeutic use)
  • Antigens, CD (immunology)
  • Antineoplastic Agents (therapeutic use)
  • Humans
  • Immunologic Factors (therapeutic use)
  • Molecular Targeted Therapy (methods)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, immunology)
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: